rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2007-3-3-68-71rpcardio-462Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯANGIOTENSIN CONVERTING ENZYME INHIBITORS IN ACUTE MYOCARDIAL INFARCTION: WHEN TO START THERAPY AND WHICH DRUG TO USE?ИНГИБИТОРЫ АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА ПРИ ОСТРОМ ИНФАРКТЕ МИОКАРДА: КОГДА НАЧИНАТЬ ТЕРАПИЮ И КАКОЙ ПРЕПАРАТ ИСПОЛЬЗОВАТЬ?МарцевичС. Ю.MartsevichS. Y.ТолпыгинаС. Н.TolpyginaS. N.Государственный научно-исследовательский центр профилактической медицины Росздрава, МоскваРоссияState Research center of preventive medicine of Roszdrav, MoscowRussian Federation200702012016336871Copyright © Martsevich S.Y., Tolpygina S.N., 20152015Марцевич С.Ю., Толпыгина С.Н.Martsevich S.Y., Tolpygina S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/462

Data of studies devoted to application of angiotensin converting enzyme (ACE) inhibitors in acute myocardial infarction are reviewed. The reasons of ambiguous results are discussed. A point of view that different ACE inhibitors may have the various efficacy and safety in patients with acute myocardial infarction is suggested.

Рассматриваются результаты исследований, в которых использовались разные схемы назначения ингибиторов ангиотензинпревращающего фермента (АПФ) при остром инфаркте миокарда. Обсуждаются причины неоднозначных результатов, полученных в этих исследованиях. Высказывается точка зрения о том, что разные ингибиторы АПФ могут обладать неодинаковой эффективностью и безопасностью при остром инфаркте миокарда.

инфаркт миокардаингибиторы ангиотензинпревращающего ферментаэффективностьбезопасностьmyocardial infarctionangiotensin converting enzyme inhibitorsefficacysafetyReferencesErtl G., Kloner R., Alexander R., Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982;65:40-8.Ertl G., Kloner R., Alexander R., Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982;65:40-8.Ertl G. Angiotensin converting enzyme inhibitors in angina and myocardial infarction. What role will they play in the 1990s? Drugs 1993;46:209-18.Ertl G. Angiotensin converting enzyme inhibitors in angina and myocardial infarction. What role will they play in the 1990s? Drugs 1993;46:209-18.Pfeffer M., Braunwald E., Moye L., et al. Effect of captopril on mortality and morbidity in patients with left ventricular disfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669- 77.Pfeffer M., Braunwald E., Moye L., et al. Effect of captopril on mortality and morbidity in patients with left ventricular disfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669- 77.The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.The TRACE Study Group. The TRAndalopril Cardiac Evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. Am J Cardiol. 1994;73:44C-50C.The TRACE Study Group. The TRAndalopril Cardiac Evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. Am J Cardiol. 1994;73:44C-50C.Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. 2003;24:28-66.Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. 2003;24:28-66.Swedberg K., Held P., Kjekhus J., et al. Effects of the early administration of enalapril on mortality in patients with myocardial infarction. Results of the Coopera￾tive New Scandinavian Enalapril Survival Study. N Engl J Med 1992;327:678-84.Swedberg K., Held P., Kjekhus J., et al. Effects of the early administration of enalapril on mortality in patients with myocardial infarction. Results of the Coopera￾tive New Scandinavian Enalapril Survival Study. N Engl J Med 1992;327:678-84.Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.ISIS-4 (Fourth International Study of Infarct Survival) Collaborative. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.ISIS-4 (Fourth International Study of Infarct Survival) Collaborative. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.Ambrosioni E., Borghi C., Magnani B., Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-convertingenzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.Ambrosioni E., Borghi C., Magnani B., Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-convertingenzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.Pfeffer M., Greaves S., Arnold M. et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. Circulation 1997;95:2643-51.Pfeffer M., Greaves S., Arnold M. et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. Circulation 1997;95:2643-51.Khali M.E., Basher A.W., Brown E.J Jr., Alhaddad I.A. A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am. Coll Cardiol 2001;37:1757-64.Khali M.E., Basher A.W., Brown E.J Jr., Alhaddad I.A. A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am. Coll Cardiol 2001;37:1757-64.Borghi C., Ambrosioni E., SMILE-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) Study. Am J Cardiol 2003;145:80-7.Borghi C., Ambrosioni E., SMILE-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) Study. Am J Cardiol 2003;145:80-7.Ball S., Hall A. Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction? Am Heart J 1996;132:244-50.Ball S., Hall A. Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction? Am Heart J 1996;132:244-50.

The authors declare that there are no conflicts of interest present.